144689-24-7 | Olmesartan

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
100mg	98%	in stock	$68.00	$48.00
250mg	98%	in stock	$147.00	$103.00
1g	98%	in stock	$379.00	$266.00
5g	98%	in stock	$1,132.00	$793.00

Description

• Catalog Number: AA72390
• Chemical Name: Olmesartan
• CAS Number: 144689-24-7
• Molecular Formula: C24H26N6O3
• Molecular Weight: 446.50164
• MDL Number: MFCD00914967
• SMILES: CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)O)C(O)(C)C
• NSC Number: 759810

Computed Properties

• Complexity: 656
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 8
• XLogP3: 3.2

Literature

• Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3.

  Chemico-biological interactions 20140125

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Comparative study of the AT₁ receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers.

  Biochimica et biophysica acta 20121201

• Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.

  The Tohoku journal of experimental medicine 20121201

• Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

  The American journal of medicine 20121001

• The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.

  Diabetes & vascular disease research 20121001

• Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20121001

• Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

  Expert review of cardiovascular therapy 20120901

• Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120801

• Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.

  Journal of cardiovascular pharmacology 20120801

• Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.

  American journal of hypertension 20120801

• Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.

  Journal of human genetics 20120801

• Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

  Hypertension (Dallas, Tex. : 1979) 20120801

• Severe spruelike enteropathy associated with olmesartan.

  Mayo Clinic proceedings 20120801

• Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120801

• Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.

  Life sciences 20120726

• Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.

  British journal of clinical pharmacology 20120701

• Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake.

  American journal of physiology. Renal physiology 20120701

• Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.

  Journal of hypertension 20120701

• Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20120601

• Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.

  Hypertension (Dallas, Tex. : 1979) 20120601

• Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.

  Hypertension (Dallas, Tex. : 1979) 20120601

• Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model.

  International journal of cardiology 20120531

• Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120512

• Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

  American journal of hypertension 20120501

• Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.

  CNS neuroscience & therapeutics 20120501

• Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.

  European review for medical and pharmacological sciences 20120501

• Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.

  Molecular and cellular endocrinology 20120404

• Angiotensin II receptor blocker combinations: from guidelines to clinical practice.

  Blood pressure 20120401

• Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?

  Revista espanola de cardiologia (English ed.) 20120401

• Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.

  Pharmaceutical biology 20120401

• Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.

  Expert opinion on pharmacotherapy 20120401

• Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.

  Journal of hypertension 20120401

• Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.

  Internal medicine journal 20120401

• [Hypertension: improved therapy adherence after switch to a fixed drug combinations].

  MMW Fortschritte der Medizin 20120322

• Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120301

• Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

• Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.

  American journal of hypertension 20120301

• In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20120301

• Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

  Circulation. Arrhythmia and electrophysiology 20120201

• Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.

  Clinica chimica acta; international journal of clinical chemistry 20120118

• Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.

  Molecular and cellular endocrinology 20120102

• Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.

  Journal of the American Society of Hypertension : JASH 20120101

• Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.

  Current medical research and opinion 20120101

• Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.

  Atherosclerosis 20120101

• Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• Olmesartan attenuates the impairment of endothelial cells induced by oxidized low density lipoprotein through downregulating expression of LOX-1.

  International journal of molecular sciences 20120101

• [Recent advance in kidney and hypertension research].

  Nihon Jinzo Gakkai shi 20120101

• Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

  Cardiovascular diabetology 20120101

• Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor.

  PloS one 20120101

• Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.

  Internal medicine (Tokyo, Japan) 20120101

• Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine.

  Cardiology 20120101

• Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers.

  Biochimica et biophysica acta 20111201

• Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

  Diabetologia 20111201

• Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.

  Experimental biology and medicine (Maywood, N.J.) 20111201

• 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.

  Journal of clinical hypertension (Greenwich, Conn.) 20111201

• Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.

  European review for medical and pharmacological sciences 20111201

• [Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20111110

• Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

  Journal of human hypertension 20111101

• Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing.

  Heart and vessels 20111101

• Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.

  Journal of gastroenterology 20111101

• Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption.

  American journal of physiology. Renal physiology 20111101

• Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.

  Journal of clinical hypertension (Greenwich, Conn.) 20111101

• Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats.

  Journal of hypertension 20111001

• Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20110901

• Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.

  Contemporary clinical trials 20110901

• Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.

  European journal of medicinal chemistry 20110901

• Severe angioedema associated with olmesartan.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20110901

• [Case of olmesartan and amlodipine intoxication].

  Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 20110901

• Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.

  Cardiovascular drugs and therapy 20110801

• Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110801

• L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110801

• 'ROADMAP' controversies.

  Journal of clinical hypertension (Greenwich, Conn.) 20110801

• Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients.

  Heart and vessels 20110701

• [Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].

  Atencion primaria 20110701

• Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats.

  Journal of hypertension 20110701

• Olmesartan, microalbuminuria, and type 2 diabetes.

  The New England journal of medicine 20110609

• Olmesartan, microalbuminuria, and type 2 diabetes.

  The New England journal of medicine 20110609

• Olmesartan, microalbuminuria, and type 2 diabetes.

  The New England journal of medicine 20110609

• Olmesartan, microalbuminuria, and type 2 diabetes.

  The New England journal of medicine 20110609

• Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.

  Journal of human hypertension 20110601

• Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110601

• Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.

  The Journal of pharmacology and experimental therapeutics 20110601

• The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.

  Journal of human hypertension 20110601

• Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20110601

• The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.

  Journal of human hypertension 20110601

• Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.

  American journal of physiology. Renal physiology 20110601

• Estrogen-independent activation of estrogen receptors.

  Hypertension (Dallas, Tex. : 1979) 20110601

• Activation of estrogen receptor-α and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats.

  Hypertension (Dallas, Tex. : 1979) 20110601

• A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

  Journal of clinical hypertension (Greenwich, Conn.) 20110601

• Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.

  Journal of clinical hypertension (Greenwich, Conn.) 20110601

• Diabetes: ROADMAP: the road to renoprotection?

  Nature reviews. Nephrology 20110524

• CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.

  Atherosclerosis 20110501

• A pooled analysis of 20 post-authorization surveys of olmesartan involving 156,682 hypertensive patients.

  Expert opinion on drug safety 20110501

• Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

  Hypertension (Dallas, Tex. : 1979) 20110501

• Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).

  Polskie Archiwum Medycyny Wewnetrznej 20110501

• Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.

  American journal of hypertension 20110401

• Reduction of albuminuria with antihypertensive treatment: is more always better?

  American journal of hypertension 20110401

• Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.

  Biopharmaceutics & drug disposition 20110401

• Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

  The New England journal of medicine 20110310

• Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.

  The New England journal of medicine 20110310

• Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110301

• Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.

  American journal of hypertension 20110301

• Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

  Atherosclerosis 20110301

• Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.

  Expert opinion on drug safety 20110301

• Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

  Hypertension (Dallas, Tex. : 1979) 20110301

• The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

  Journal of clinical hypertension (Greenwich, Conn.) 20110201

• Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.

  Chinese medical journal 20110201

• Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.

  International journal of cardiology 20110121

• Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110101

• Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.

  American journal of physiology. Heart and circulatory physiology 20110101

• Angiotensin II receptor blocker induced fetopathy: 7 cases.

  Klinische Padiatrie 20110101

• Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.

  Kidney & blood pressure research 20110101

• Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis.

  International journal of biological sciences 20110101

• Olmesartan/amlodipine: a review of its use in the management of hypertension.

  Vascular health and risk management 20110101

• Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.

  Journal of medical economics 20110101

• Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.

  Kidney & blood pressure research 20110101

• Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

  Vascular health and risk management 20110101

• Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.

  Cardiovascular diabetology 20110101

• Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20110101

• [Multicenter trial of olmesartan. Main results].

  Terapevticheskii arkhiv 20110101

• Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.

  Bioorganic & medicinal chemistry 20101215

• Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.

  Kidney international 20101201

• Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care.

  Expert opinion on pharmacotherapy 20101201

• Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101201

• Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101201

• Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.

  Biomedical chromatography : BMC 20101201

• Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.

  Journal of human hypertension 20101101

• The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101101

• Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.

  Free radical research 20101101

• Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.

  Experimental biology and medicine (Maywood, N.J.) 20101101

• Metabolic regulation of coronary vascular tone: role of hydrogen peroxide, purinergic components, and angiotensin.

  European journal of pharmacology 20101025

• An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats.

  Journal of neuroscience research 20101001

• A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.

  American journal of physiology. Renal physiology 20101001

• Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.

  Bioorganic & medicinal chemistry letters 20101001

• Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.

  Therapeutic advances in cardiovascular disease 20101001

• Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.

  European review for medical and pharmacological sciences 20100901

• Porphyria cutanea tarda induced by olmesartan.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20100801

• Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100801

• Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.

  Therapeutic advances in cardiovascular disease 20100801

• Pharmacological therapy for hypertensive children: an 'additional bypass' of lifestyle interventions.

  Hypertension (Dallas, Tex. : 1979) 20100801

• Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats.

  Annals of vascular surgery 20100801

• Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form.

  Journal of chromatographic science 20100801

• Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways.

  Journal of atherosclerosis and thrombosis 20100630

• AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.

  Atherosclerosis 20100601

• Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.

  Expert opinion on pharmacotherapy 20100601

• Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

  Journal of clinical hypertension (Greenwich, Conn.) 20100601

• Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice.

  Hypertension (Dallas, Tex. : 1979) 20100501

• The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke.

  The International journal of neuroscience 20100501

• Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20100501

• ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.

  American journal of physiology. Renal physiology 20100401

• Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.

  Circulation journal : official journal of the Japanese Circulation Society 20100401

• Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100401

• Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.

  Brain research 20100331

• Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100315

• Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.

  Journal of the American College of Cardiology 20100309

• Plaque burden with composition? That is the next question.

  Journal of the American College of Cardiology 20100309

• Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.

  Atherosclerosis 20100301

• Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.

  Current medical research and opinion 20100301

• Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.

  Journal of hypertension 20100301

• Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

  Biopharmaceutics & drug disposition 20100301

• Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

  Clinical therapeutics 20100301

• Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.

  Life sciences 20100227

• Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100201

• Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100201

• Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

  Diabetologia 20100101

• Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure.

  Journal of cardiovascular pharmacology 20100101

• Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model.

  Cardiovascular therapeutics 20100101

• Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

  Advances in therapy 20100101

• Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.

  Nutricion hospitalaria 20100101

• Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.

  Journal of pharmacological sciences 20100101

• The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Role of olmesartan in combination therapy in blood pressure control and vascular function.

  Vascular health and risk management 20100101

• Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.

  Vascular health and risk management 20100101

• Olmesartan associated with acute renal failure in a patient with bilateral renal artery stenosis.

  Renal failure 20100101

• Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091201

• Angiotensin II and hypertonicity modulate proximal tubular aquaporin 1 expression.

  American journal of physiology. Renal physiology 20091201

• Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling.

  Hypertension (Dallas, Tex. : 1979) 20091201

• Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients.

  Brain injury 20091201

• Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.

  Biological & pharmaceutical bulletin 20091201

• Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091101

• Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091101

• Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20091101

• Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091001

• Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091001

• Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.

  Hypertension (Dallas, Tex. : 1979) 20091001

• Central blood pressure under angiotensin and calcium channel blockade.

  Hypertension (Dallas, Tex. : 1979) 20091001

• Does treatment with olmesartan improve arterial stenoses due to fibromuscular dysplasia?

  Hypertension research : official journal of the Japanese Society of Hypertension 20091001

• Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.

  American journal of hypertension 20091001

• Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.

  Journal of atherosclerosis and thrombosis 20091001

• Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.

  Drug metabolism and disposition: the biological fate of chemicals 20090901

• Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.

  Current medical research and opinion 20090901

• Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20090901

• AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.

  Translational research : the journal of laboratory and clinical medicine 20090901

• Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters.

  Journal of pharmacological sciences 20090901

• Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease.

  Annals of the New York Academy of Sciences 20090901

• Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice.

  Clinical and experimental pharmacology & physiology 20090801

• Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.

  Endocrinology 20090801

• Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.

  Journal of hypertension 20090801

• Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090801

• Renal and vascular glutathione S-transferase mu is not affected by pharmacological intervention to reduce systolic blood pressure.

  Journal of hypertension 20090801

• Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090801

• Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.

  The American journal of cardiology 20090801

• 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.

  Journal of clinical hypertension (Greenwich, Conn.) 20090801

• Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).

  Hypertension research : official journal of the Japanese Society of Hypertension 20090701

• Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090701

• Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090701

• Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.

  Journal of cardiovascular pharmacology 20090701

• Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.

  Heart and vessels 20090701

• Study of the acute cardiovascular effects of several antihypertensive agents with the measurement of plasma catecholamines in mice.

  Analytical and bioanalytical chemistry 20090601

• Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090601

• Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II.

  American journal of physiology. Renal physiology 20090501

• Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090501

• Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.

  International journal of clinical practice 20090501

• Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats.

  Heart and vessels 20090501

• Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.

  Clinical and experimental nephrology 20090401

• Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.

  Therapeutic advances in cardiovascular disease 20090401

• Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice.

  Hypertension (Dallas, Tex. : 1979) 20090201

• Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.

  American journal of hypertension 20090201

• Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.

  Laboratory investigation; a journal of technical methods and pathology 20090201

• Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.

  Current medical research and opinion 20090201

• Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats.

  Acta medica Okayama 20090201

• Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090201

• Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells.

  American journal of nephrology 20090101

• Angiotensin II type 1 receptor antagonists prevent glucose-induced increases in islet blood flow in rats.

  Scandinavian journal of clinical and laboratory investigation 20090101

• Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.

  Diabetes research and clinical practice 20090101

• Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].

  Advances in therapy 20090101

• Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.

  Chronobiology international 20090101

• Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis.

  Journal of gastroenterology 20090101

• Antiproteinuric effect of olmesartan in patients with IgA nephropathy.

  Journal of nephrology 20090101

• Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.

  Pharmacology 20090101

• Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.

  Drug metabolism and pharmacokinetics 20090101

• Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.

  Kidney & blood pressure research 20090101

• Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.

  Nephrology (Carlton, Vic.) 20081201

• Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.

  Cardiovascular research 20081201

• Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.

  Journal of molecular and cellular cardiology 20081201

• Angiotensin type 1 receptor blockade prevents cardiac remodeling in mice with pregnancy-associated hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20081201

• Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

  Vascular health and risk management 20081201

• Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats.

  American journal of physiology. Renal physiology 20081101

• Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.

  Journal of clinical pharmacology 20081101

• Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule.

  Hypertension (Dallas, Tex. : 1979) 20081001

• Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.

  International journal of molecular medicine 20081001

• Successful treatment of post-MRSA infection glomerulonephritis with steroid therapy.

  Clinical nephrology 20081001

• Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.

  American journal of physiology. Heart and circulatory physiology 20080901

• Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.

  Hypertension (Dallas, Tex. : 1979) 20080901

• Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.

  The American journal of pathology 20080801

• Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats.

  Journal of hypertension 20080801

• Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.

  European journal of pharmacology 20080707

• Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells.

  American journal of physiology. Renal physiology 20080701

• Quality of life in hypertension management using olmesartan in primary care.

  Expert opinion on pharmacotherapy 20080701

• [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].

  Zhonghua yi xue za zhi 20080610

• Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.

  Diabetes 20080601

• Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.

  Nephrology (Carlton, Vic.) 20080601

• Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis.

  American journal of physiology. Heart and circulatory physiology 20080601

• Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure.

  Hypertension (Dallas, Tex. : 1979) 20080601

• The collecting duct is the major source of prorenin in diabetes.

  Hypertension (Dallas, Tex. : 1979) 20080601

• [High-performance liquid chromatography-mass spectrometry for determining olmesartan in human plasma].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.

  Vascular health and risk management 20080601

• [Lowering blood pressure and more? AT1 antagonist reduced plaque volume].

  MMW Fortschritte der Medizin 20080501

• Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080501

• Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?

  Annals of the New York Academy of Sciences 20080401

• Oxidative stress in mononuclear cells plays a dominant role in their adhesion to mouse femoral artery after injury.

  Hypertension (Dallas, Tex. : 1979) 20080301

• Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis.

  Journal of hypertension 20080301

• Unusual detritylation of tritylated tetrazole in Sartan molecules.

  Chemical & pharmaceutical bulletin 20080301

• Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080301

• Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080301

• Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080201

• Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.

  Microvascular research 20080101

• Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.

  Molecular endocrinology (Baltimore, Md.) 20080101

• Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.

  Ophthalmic research 20080101

• Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.

  Internal medicine (Tokyo, Japan) 20080101

• Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors.

  Pharmacology 20080101

• Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.

  Respiratory research 20080101

• Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.

  La Pediatria medica e chirurgica : Medical and surgical pediatrics 20080101

• Two amlodipine/ARB combinations for hypertension.

  The Medical letter on drugs and therapeutics 20071217

• Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.

  Drug metabolism and disposition: the biological fate of chemicals 20071201

• Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.

  Journal of hypertension 20071201

• Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan.

  Neuropharmacology 20071201

• Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model.

  Circulation journal : official journal of the Japanese Circulation Society 20071201

• Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20071201

• Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.

  Therapeutic advances in cardiovascular disease 20071201

• Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

  American journal of hypertension 20071101

• Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.

  American journal of hypertension 20071001

• Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance.

  Hypertension research : official journal of the Japanese Society of Hypertension 20071001

• Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.

  Journal of the American College of Cardiology 20070918

• Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.

  Journal of human hypertension 20070901

• Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901

• Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20070901

• Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

  British journal of pharmacology 20070801

• Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

  British journal of pharmacology 20070801

• Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.

  Drug metabolism and pharmacokinetics 20070801

• Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread.

  Cancer biology & therapy 20070801

• [Acute renal failure induced by angiotensin II receptor blocker in a patient with horseshoe kidney].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070610

• An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.

  Physiology & behavior 20070608

• Regulation of scavenger receptor class BI gene expression by angiotensin II in vascular endothelial cells.

  Hypertension (Dallas, Tex. : 1979) 20070601

• Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20070601

• [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan.

  American journal of physiology. Heart and circulatory physiology 20070501

• Effect of olmesartan on oxidative stress in hemodialysis patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070501

• Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.

  Journal of the American College of Cardiology 20070403

• Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice.

  Journal of molecular and cellular cardiology 20070401

• Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats.

  Diabetes research and clinical practice 20070301

• Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.

  Arteriosclerosis, thrombosis, and vascular biology 20070301

• A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

  The Journal of endocrinology 20070301

• Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.

  Journal of hypertension 20070201

• Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model.

  Journal of the American Society of Nephrology : JASN 20070201

• Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

  The Journal of pharmacology and experimental therapeutics 20070101

• Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system.

  Nephron. Experimental nephrology 20070101

• Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

  Journal of clinical hypertension (Greenwich, Conn.) 20070101

• Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.

  Chronobiology international 20070101

• Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.

  The Journal of pharmacology and experimental therapeutics 20061201

• Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.

  Kidney international 20061101

• Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.

  Journal of hypertension 20061101

• Angiotensin II regulates migration in mouse cultured mesangial cells: evidence for the presence of receptor subtype-specific regulation.

  The Journal of endocrinology 20061101

• Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.

  Hypertension research : official journal of the Japanese Society of Hypertension 20061101

• Letter by Krop et al regarding article, 'Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium'.

  Circulation 20061024

• Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20061001

• Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells.

  Hypertension (Dallas, Tex. : 1979) 20061001

• The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

  Journal of hypertension 20061001

• Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.

  American journal of physiology. Heart and circulatory physiology 20060901

• Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy.

  Laboratory investigation; a journal of technical methods and pathology 20060901

• Olmesartan, migraine, and blood pressure.

  Headache 20060901

• Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060901

• Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor.

  The Journal of biological chemistry 20060714

• Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.

  Current medical research and opinion 20060701

• OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

  Drug metabolism and disposition: the biological fate of chemicals 20060501

• Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060501

• Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance.

  Metabolism: clinical and experimental 20060401

• Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.

  Clinical science (London, England : 1979) 20060301

• Prevention of migraine with olmesartan in patients with hypertension/prehypertension.

  Headache 20060301

• Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060301

• Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

  Journal of hypertension 20060201

• Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.

  Blood pressure 20060101

• Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy.

  Advances in therapy 20060101

• Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.

  Journal of hypertension 20051101

• [Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].

  Presse medicale (Paris, France : 1983) 20051022

• Chronic administration of olmesartan attenuates the exaggerated pressor response to glutamate in the rostral ventrolateral medulla of SHR.

  Brain research 20051005

• Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery.

  British journal of pharmacology 20051001

• The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet.

  Journal of hypertension 20051001

• Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome.

  Respiratory medicine 20050901

• Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050901

• Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent.

  International journal of pharmaceutics 20050811

• Mechanism of permeability-enhancing effect of EDTA and boric acid on the corneal penetration of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088).

  International journal of pharmaceutics 20050811

• Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats.

  Journal of hypertension 20050801

• Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats.

  Journal of the American Society of Nephrology : JASN 20050701

• Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.

  American journal of hypertension 20050701

• Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats.

  Hypertension (Dallas, Tex. : 1979) 20050601

• Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes.

  Experimental eye research 20050501

• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.

  The American journal of the medical sciences 20050501

• Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.

  European journal of pharmacology 20050411

• Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Synergistic effect of EDTA and boric acid on corneal penetration of CS-088.

  International journal of pharmaceutics 20050216

• ['High dosage monotherapy'].

  Krankenpflege Journal 20050101

• Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells.

  Antioxidants & redox signaling 20050101

• [Olmesartan after experimental myocardial infarct compared with ramipril: organ protective effect].

  Krankenpflege Journal 20050101

• Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

  Clinical pharmacokinetics 20050101

• The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.

  Proceedings of the Western Pharmacology Society 20050101

• Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.

  Circulation 20040810

• Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20040701

• Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

  Drugs 20040101

• Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.

  Cardiovascular drug reviews 20040101

• Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes.

  Cardiovascular drugs and therapy 20030501

• Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.

  Journal of cardiovascular pharmacology 20030101

• CS-088, an angiotensin type 1 receptor antagonist, ameliorated the impaired blood flow in the optic nerve head of rabbits.

  Ophthalmic research 20030101

• Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.

  Journal of the American College of Cardiology 20020703

• Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20020701

• Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor.

  Journal of cardiovascular pharmacology 20020201

• The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits.

  Current eye research 20010801

• The effect of angiotensin II on uveoscleral outflow in rabbits.

  Current eye research 20010801

• The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

• Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects.

  Journal of clinical pharmacology 20010501